DDInter1642 DDInter909
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Imatinib {u} (Compound) resembles {v} (Compound) Buclizine
Imatinib {u} (Compound) treats {v} (Disease) hematologic cancer
Imatinib {u} (Compound) binds {v} (Gene) CA12
Imatinib {u} (Compound) upregulates {v} (Gene) MEF2C
Imatinib {u} (Compound) downregulates {v} (Gene) DECR1
Imatinib {u} (Compound) causes {v} (Side Effect) Eye disorder
Imatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Imatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixabepilone
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Imatinib (Compound) resembles Buclizine (Compound)
Imatinib (Compound) treats hematologic cancer (Disease)
Imatinib (Compound) binds CA12 (Gene)
Imatinib (Compound) upregulates MEF2C (Gene)
Imatinib (Compound) downregulates DECR1 (Gene)
Imatinib (Compound) causes Eye disorder (Side Effect)
Imatinib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Imatinib may cause a minor interaction that can limit clinical effects when taken with Citalopram
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab